<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731080</article-id><article-id pub-id-type="pmc">PMC11681697</article-id><article-id pub-id-type="publisher-id">13358</article-id><article-id pub-id-type="doi">10.1186/s12885-024-13358-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Gene expression profiling for the diagnosis of male breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Yifeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Peng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wo</surname><given-names>Yixin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Qinghua</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xu</surname><given-names>Midie</given-names></name><address><email>xumd@shca.org.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Shenglin</given-names></name><address><email>slhuang@fudan.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Qifeng</given-names></name><address><email>wangqifeng19821982@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Department of Pathology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff2"><label>2</label>Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd, Hangzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>24</volume><elocation-id>1584</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Male breast cancer (MBC) is a rare malignancy, but its global incidence has shown a notable increase in recent decades. Factors such as limited health literacy, inadequate health education, and reluctance to seek medical attention contribute to the late-stage diagnosis of most MBC patients. Consequently, there is an urgent need for a highly specific and sensitive diagnostic approach to MBC.</p></sec><sec><title>Methods</title><p id="Par2">This retrospective study enrolled 20 patients with 30 surgical or biopsy MBC specimens from August 2020 to August 2023. The 90-gene expression assay was performed to determine the tissue of origin. Predicted tumor types were then compared to the reference diagnosis for accuracy calculation. The differentially expressed genes were identified between male and female breast cancer.</p></sec><sec><title>Result</title><p id="Par3">The 90-gene expression assay demonstrated an overall accuracy of 96.7% (29/30) when compared with the pathological diagnosis. For primary, lymph node metastatic, and distant metastatic tumors, the accuracies were 100% (15/15), 90.9% (10/11), and 100% (4/4), respectively. Five genes (<italic>RPS4Y1</italic>,<italic> PI15</italic>,<italic> AZGP1</italic>,<italic> PRRX1</italic>, and <italic>AGR2</italic>) were up-regulated, and six (<italic>XIST</italic>,<italic> PIGR</italic>,<italic> SFRP1</italic>,<italic> PLA2G2A</italic>,<italic> S100A2</italic>, and <italic>CHI3L1</italic>) were down-regulated in MBC.</p></sec><sec><title>Conclusion</title><p id="Par4">Our findings highlight the promising performance of the 90-gene expression assay in accurately identifying the tumor origin in MBC. Incorporating this assay into pathological diagnoses has the potential to empower oncologists with precision treatment options, ultimately enhancing the care and outcomes for patients with MBC.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12885-024-13358-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Male breast cancer</kwd><kwd>Gene expression profile</kwd><kwd>Tissue of origin</kwd></kwd-group><funding-group><award-group><funding-source><institution>Canhelp Genomics Co., Ltd</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>81,972,728</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Male breast cancer (MBC) is a rare malignancy, accounting for less than 1% of all breast cancer cases but its global incidence has increased over recent decades [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The etiology and pathogenesis of MBC remain unclear. Studies have shown that risk factors for MBC include a family history of breast cancer, older age, carrying a predisposition germline genetic mutation (e.g., <italic>BRCA 1/2</italic>), hormonal imbalance, and exposure to radiation [<xref ref-type="bibr" rid="CR3">3</xref>]. Owing to factors such as illiteracy, inadequate health education, and reluctance to report symptoms to the clinical physician, most MBC patients present at an advanced stage [<xref ref-type="bibr" rid="CR4">4</xref>]. A study conducted at a single institution in Italy reported distant metastasis in 32% of MBC patients, primarily affecting the lungs and bones [<xref ref-type="bibr" rid="CR5">5</xref>]. Consequently, precise diagnosis of MBC is essential for selecting appropriate treatment and improving prognosis.</p><p id="Par22">Male breast tissue is typically less developed than its female counterpart, rendering physical examination and imaging interpretation more challenging [<xref ref-type="bibr" rid="CR6">6</xref>]. Both mammography and magnetic resonance imaging have limited diagnostic value in MBC [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Histopathology is considered the gold standard for diagnosing MBC metastases. Various immunohistochemical markers including androgen receptor (AR), GATA3, mammaglobin (MGB), and gross cystic disease fluid protein-15 (GCDFP15), play a crucial role in diagnosing the majority of metastatic MBC [<xref ref-type="bibr" rid="CR1">1</xref>]. However, due to the rarity of MBC and the lack of awareness among both patients and healthcare professionals, misdiagnosis or delayed diagnosis of MBC is prevalent [<xref ref-type="bibr" rid="CR9">9</xref>]. Thus, identifying the tissue of origin of metastatic MBC, especially in patients without a prior history of breast cancer, is challenging. Furthermore, survivors of MBC face elevated risks of developing second primary cancers [<xref ref-type="bibr" rid="CR10">10</xref>]. Accurate diagnosis of second primary cancers or MBC metastasis is crucial for selecting appropriate therapy.</p><p id="Par23">As the field of oncology continues to evolve towards precision medicine including targeted therapy, immune checkpoint inhibitors, chimeric antigen receptor T cell therapy, and cancer vaccines, etc., the integration of molecular diagnostics has become increasingly important [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Previously, our research group developed a 90-gene expression assay (Canhelp-Origin Test) to identify 21 common tumor types using real-time PCR methods with total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue [<xref ref-type="bibr" rid="CR14">14</xref>]. In a large-scale multicenter study comprising 1417 samples, the 90-gene expression assay demonstrated an accuracy of 94.4% and a specificity exceeding 99% [<xref ref-type="bibr" rid="CR15">15</xref>]. A randomized phase III trial demonstrated that site-specific treatment guided by the 90-gene-expression assay resulted in more therapy options, significantly improved progression free survival and favorable overall survival compared with empirical chemotherapy in patients with cancer of unknown primary [<xref ref-type="bibr" rid="CR16">16</xref>]. In the present study, we conducted a retrospective study to assess the performance of the 90-gene expression assay and explore its potential diagnostic utility for MBC.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patient enrollment and specimen acquisition</title><p id="Par24">The study was conducted with approval from the institutional review board of Fudan University Shanghai Cancer Center (FUSCC, Shanghai, China). We collected surgical or biopsy specimens, along with associated clinicopathologic data. Inclusion criteria were: (1) FFPE tissues, (2) the reference diagnosis was male breast cancer (3) more than 60% tumor cell content, and less than 40% necrosis as assessed by Hematoxylin and Eosin (H&#x00026;E) staining [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Clinicopathological characteristics</title><p id="Par25">Patient demographics including age, tumor site, tumor dimensions, lymph node involvement, and surgical approach were meticulously documented from medical records. Tumor staging was conducted according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system [<xref ref-type="bibr" rid="CR17">17</xref>]. Diagnoses were confirmed through an independent review of all case slides by two pathologists (QF W and J L). Histological types were characterized according to the World Health Organization (WHO) guidelines [<xref ref-type="bibr" rid="CR18">18</xref>], while histological grading for invasive cancers was defined using a modified Bloom and Richardson scoring scheme [<xref ref-type="bibr" rid="CR19">19</xref>]. Immunohistochemical analyses were performed on 4&#x000a0;&#x003bc;m sections of FFPE tissues, with a detailed list of all antibodies utilized provided in Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec5"><title>Sample preparation and RNA isolation</title><p id="Par26">A range of five to fifteen unstained sections, each 5&#x000a0;&#x003bc;m thick, were prepared and centralized for analysis. Pathologists QF W and J L reviewed H&#x00026;E-stained slides to assess the tumor cell content, identify tumor regions, and manually perform macro-dissection for enrichment. Adhering to established protocols, total RNA was extracted utilizing the FFPE total RNA Isolation Kit (Canhelp Genomics Co., Ltd., Hangzhou, China) [<xref ref-type="bibr" rid="CR14">14</xref>]. Subsequently, the concentration and purity were measured using a spectrophotometer.</p></sec><sec id="Sec6"><title>Gene expression profiling analysis</title><p id="Par27">The 90-gene expression assay (Canhelp Genomics Co., Ltd) was executed in adherence to established protocols, encompassing reverse transcription of total RNA and real-time PCR reaction for comprehensive tumor-specific gene expression profiling [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The results of the 90-gene expression assay were reported if they met the PCR analytical quality control threshold for internal controls (cycle threshold value less than 38) and no template control (cycle threshold value larger than 38) [<xref ref-type="bibr" rid="CR20">20</xref>]. For each case, the prespecified 90-gene classifier was utilized to analyze the gene expression patterns and generate similarity scores for every primary tumor type. These scores are probability-based, ranging from 0 to 100, and the total of all 21 similarity scores for each sample sums to 100. The tumor type with the highest similarity score was considered the predicted type.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par28">Statistical analyses were conducted using R software (version 3.6.1) and Bioconductor packages (version 3.9). Hierarchical clustering of specimens based on gene expression profiling was performed with the &#x0201c;pheatmap&#x0201d; package (version 1.0.12). Differentially expressed genes between MBC and FBC were identified using the &#x0201c;limma&#x0201d; package (version 3.54.2) with Benjamini-Hochberg (B-H) p-value&#x02009;&#x0003c;&#x02009;0.01.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Patients and samples</title><p id="Par29">Initially, 20 patients archived from August 2020 and August 2023 were enrolled in this study, yielding 30 FFPE specimens, comprising 15 primary breast tumors (PBT), 11 lymph node metastases (LNM), and 4 distant organ metastases (DOM). Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> displays the clinicopathological characteristics of 20 patients. The median age at diagnosis was 65.5 years for all patients. Among the PBT cases, 10 occurred in the left breast and 5 in the right. Eight tumors measured less than 2&#x000a0;cm, and seven ranged between 2 and 5&#x000a0;cm. All histological subtypes were identified as invasive ductal carcinoma, with two cases exhibiting invasive ductal carcinoma coexisting with invasive micropapillary carcinoma. Surgical interventions comprised modified radical mastectomy (<italic>N</italic>&#x02009;=&#x02009;11), simple mastectomy (<italic>N</italic>&#x02009;=&#x02009;3), and simple mastectomy with sentinel lymph node biopsy (<italic>N</italic>&#x02009;=&#x02009;1). Histologically, 12 (80%) PBTs were classified as Grade 2, and 3 (20%) were classified as Grade 3. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> provides detailed clinical and immunohistochemistry (IHC) staining features of MBC. For each case, clinical parameters such as age, tumor size (in cm), and pathological staging are presented. The IHC results indicated positive staining for estrogen receptor (ER) (18/19, 94.7%), progesterone receptor (PR) (17/20, 85.0%), GATA3 (20/20, 100%), HER2 (3/20, 15.0%), AR (17/19, 89.5%), GCDFP15 (16/18, 88.9%), TRPS1 (13/13, 100%), and MGB (2/4, 50.0%).</p><p id="Par30">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient&#x02019;s general characteristics included in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Primary tumor/paired lymph node metastasis</th><th align="left">Distant organ metastasis</th></tr></thead><tbody><tr><td align="left">No. patients</td><td align="left">15/11</td><td align="left">4</td></tr><tr><td align="left">Age (years)</td><td align="left" colspan="2">65.5 (27&#x02009;&#x0223c;&#x02009;86)</td></tr><tr><td align="left">Pathological type</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;IDC</td><td align="left">13/10</td><td align="left">4</td></tr><tr><td align="left">&#x02003;IDC with invasive micropapillary</td><td align="left">2/1</td><td align="left">0</td></tr><tr><td align="left">Tumor site</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Left</td><td align="left">10/7</td><td align="left">/</td></tr><tr><td align="left">&#x02003;Right</td><td align="left">5/4</td><td align="left">/</td></tr><tr><td align="left">Tumor size (cm)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;&#x02264;&#x02009;2</td><td align="left">8</td><td align="left">/</td></tr><tr><td align="left">&#x02003;2&#x02013;5</td><td align="left">7</td><td align="left">/</td></tr><tr><td align="left">Surgical approach</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Modified mastectomy</td><td align="left">11</td><td align="left"/></tr><tr><td align="left">&#x02003;Simple mastectomy with SLN</td><td align="left">1</td><td align="left"/></tr><tr><td align="left">&#x02003;Simple mastectomy</td><td align="left">3</td><td align="left"/></tr><tr><td align="left">Histological grade</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;1</td><td align="left">0</td><td align="left">/</td></tr><tr><td align="left">&#x02003;2</td><td align="left">12</td><td align="left">/</td></tr><tr><td align="left">&#x02003;3</td><td align="left">3</td><td align="left">/</td></tr><tr><td align="left">Metastatic sites</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Lung</td><td align="left">/</td><td align="left">2</td></tr><tr><td align="left">&#x02003;Bone</td><td align="left">/</td><td align="left">1</td></tr><tr><td align="left">&#x02003;Thoracic wall</td><td align="left">/</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p>IDC: Invasive ductal carcinoma; SLN: Sentinel lymph node; /: Censored value</p></table-wrap-foot></table-wrap>
</p><p id="Par31">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical information and immunohistochemistry staining features of male breast cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">no.</th><th align="left">Type</th><th align="left">Age</th><th align="left">Size (cm)</th><th align="left">pT</th><th align="left">pN</th><th align="left">M</th><th align="left">ER</th><th align="left">PR</th><th align="left">HER2<break/>(IHC)</th><th align="left">HER2<break/>(FISH)</th><th align="left">GATA3</th><th align="left">AR</th><th align="left">GCDFP15</th><th align="left">TRPS1</th><th align="left">MGB</th></tr></thead><tbody><tr><td align="left">1/2</td><td align="left">PBT/LNM</td><td char="." align="char">27</td><td align="left">5</td><td align="left">2</td><td align="left">1a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">2 +</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">3/4</td><td align="left">PBT/LNM</td><td char="." align="char">67</td><td align="left">2.5</td><td align="left">2</td><td align="left">1a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1 +</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">5/6</td><td align="left">PBT/LNM</td><td char="." align="char">68</td><td align="left">1</td><td align="left">1b</td><td align="left">2a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1 +</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">7/8</td><td align="left">PBT/LNM</td><td char="." align="char">70</td><td align="left">3</td><td align="left">2</td><td align="left">1a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">9/10</td><td align="left">PBT/LNM</td><td char="." align="char">73</td><td align="left">2</td><td align="left">1c</td><td align="left">1a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">11/12</td><td align="left">PBT/LNM</td><td char="." align="char">44</td><td align="left">1.1</td><td align="left">1c</td><td align="left">1a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">13/14</td><td align="left">PBT/LNM</td><td char="." align="char">63</td><td align="left">2.5</td><td align="left">2</td><td align="left">3a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">2+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">15/16</td><td align="left">PBT/LNM</td><td char="." align="char">69</td><td align="left">1.8</td><td align="left">1c</td><td align="left">2a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">0</td><td align="left">/</td><td align="left">+</td><td align="left">-</td><td align="left">+</td><td align="left">/</td><td align="left">-</td></tr><tr><td align="left">17/18</td><td align="left">PBT/LNM</td><td char="." align="char">57</td><td align="left">3</td><td align="left">2</td><td align="left">2a</td><td align="left">0</td><td align="left">-</td><td align="left">-</td><td align="left">3+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">19/20</td><td align="left">PBT/LNM</td><td char="." align="char">86</td><td align="left">2</td><td align="left">1c</td><td align="left">3a</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">2+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">21</td><td align="left">PBT</td><td char="." align="char">52</td><td align="left">3.2</td><td align="left">2</td><td align="left">0</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">-</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">22</td><td align="left">PBT</td><td char="." align="char">60</td><td align="left">1.3</td><td align="left">1c</td><td align="left">0</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">-</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">23</td><td align="left">PBT</td><td char="." align="char">70</td><td align="left">3</td><td align="left">2</td><td align="left">0</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">2+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">24</td><td align="left">PBT</td><td char="." align="char">67</td><td align="left">2</td><td align="left">1c</td><td align="left">0</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">0</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">25</td><td align="left">PBT</td><td char="." align="char">67</td><td align="left">1.5</td><td align="left">1c</td><td align="left">0</td><td align="left">0</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">26</td><td align="left">LNM</td><td char="." align="char">74</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">27</td><td align="left">DOM</td><td char="." align="char">44</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">0</td><td align="left">/</td><td align="left">+</td><td align="left">/</td><td align="left">/</td><td align="left">+</td><td align="left">/</td></tr><tr><td align="left">28</td><td align="left">DOM</td><td char="." align="char">62</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">29</td><td align="left">DOM</td><td char="." align="char">64</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">+</td><td align="left">-</td><td align="left">1+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">-</td></tr><tr><td align="left">30</td><td align="left">DOM</td><td char="." align="char">53</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">-</td><td align="left">3+</td><td align="left">/</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">/</td><td align="left">+</td></tr></tbody></table><table-wrap-foot><p>PBT: Primary tumor; LNM: Lymph node metastasis; DOM: Distant organ metastasis</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Performance of the 90-gene expression assay in male breast cancer</title><p id="Par32">Total RNA was isolated from FFPE sections of 30 samples. Concentrations ranged from 9.7 to 671.1 ng/&#x000b5;L, with a median concentration of 224.5 ng/&#x000b5;L. The A260/A280 ratio ranged from 1.84 to 1.95. All specimens met all quality control criteria and were successfully analyzed using the 90-gene expression assay.</p><p id="Par33">The results showed an overall concordance rate of 96.7% (29/30) with the reference diagnoses. Specifically, the consistency rates were 100% (15/15) for PBT cases, 90.9% (10/11) for LNM cases, and 100% (4/4) for DOM cases (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The median similarity scores generated by the 90-gene expression assay were 97.2 (range 63.3&#x02009;&#x0223c;&#x02009;98.8) for PBT, 92.3 (range 57.5&#x02009;&#x0223c;&#x02009;98.4) for LNM, and 86.4 (range 79.3&#x02009;&#x0223c;&#x02009;87.5) for DOM (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). The differences in the similarity scores between paired specimens (PBT and LNM) are depicted in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B.</p><p id="Par34">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Performance of 90-gene expression assay in male breast cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Tumor type</th><th align="left">
<italic>n</italic>
</th><th align="left">Agreement</th><th align="left">Accuracy (%)</th></tr></thead><tbody><tr><td align="left">Primary male breast cancer</td><td char="." align="char">15</td><td char="." align="char">15</td><td align="left">100</td></tr><tr><td align="left">Lymph node metastasis</td><td char="." align="char">11</td><td char="." align="char">10</td><td align="left">90.9</td></tr><tr><td align="left">Distant organ metastasis</td><td char="." align="char">4</td><td char="." align="char">4</td><td align="left">100</td></tr><tr><td align="left">Total accuracy</td><td char="." align="char">30</td><td char="." align="char">29</td><td align="left">96.7</td></tr></tbody></table></table-wrap>
</p><p id="Par35">
<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>(A)</bold> The distribution of similarity score for the PBT (red dots), LNM (green dots), and DOM (cyan dots), <bold>(B)</bold> The similarity score of 10 paired PBT and LNM samples, <bold>(C)</bold> The distribution of similarity score for the female (blue dots) and male (red dots) breast cancer</p></caption><graphic xlink:href="12885_2024_13358_Fig1_HTML" id="d33e1484"/></fig>
</p></sec><sec id="Sec11"><title>Comparison of the gene expression profiling between male and female breast cancer</title><p id="Par36">This study further included 54 cases of female breast cancer (FBC) for comparison of gene expression profiling with MBC. These specimens included 19 cases of metastatic breast cancer from the study by Wang et al. [<xref ref-type="bibr" rid="CR21">21</xref>] and 35 cases of primary breast cancer from the study by Sun et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. The distribution of similarity scores for MBC (median 92.7, range 35.5&#x02013;98.8) and FBC (median 90.9, range 48.4&#x02013;98.6) is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C. Hierarchical clustering based on the 90 genes revealed a distinct separation between 30 cases of MBC and 54 cases of FBC <bold>(</bold>Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A<bold>)</bold>.</p><p id="Par37">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Hierarchical clustering analysis was conducted on <bold>(A)</bold> 90 genes and <bold>(B)</bold> 11 differentially expressed genes across 84 specimens. The left panel displays a dendrogram depicting the hierarchical clustering of genes. Colored pixels represent the magnitude of the gene expression intensities, with shades of red and blue indicating over-expression and under-expression, respectively, relative to the mean for each gene. The upper panel shows a dendrogram illustrating the hierarchical clustering of samples. The upper panel indicates clinical features including the gender of each sample</p></caption><graphic xlink:href="12885_2024_13358_Fig2_HTML" id="d33e1525"/></fig>
</p><p id="Par38">Furthermore, differentially expressed genes were identified from the 90-gene panel comparing MBC and FBC, with B-H adjusted p-value below 0.01. Among them, five genes (<italic>RPS4Y1</italic>,<italic> PI15</italic>,<italic> AZGP1</italic>,<italic> PRRX1</italic>, and <italic>AGR2</italic>) were up-regulated, and six genes (<italic>XIST</italic>,<italic> PIGR</italic>,<italic> SFRP1</italic>,<italic> PLA2G2A</italic>,<italic> S100A2</italic>, and <italic>CHI3L1</italic>) were down-regulated in MBC <bold>(</bold>Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B<bold>)</bold>. Further details about these genes are described in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par39">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Desription of 5 up-regulated and 6 down-regulated genes in male breast cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Symbol</th><th align="left">Description</th><th align="left">Cytoband</th><th align="left"><italic>P</italic>-value</th><th align="left">adjusted <italic>P</italic>-value</th><th align="left">Regulation (MBC/FBC)</th></tr></thead><tbody><tr><td align="left">RPS4Y1</td><td align="left">Ribosomal Protein S4 Y-Linked 1</td><td align="left">Yp11.2</td><td align="left">3.09E-49</td><td align="left">2.78E-47</td><td align="left">Up</td></tr><tr><td align="left">PI15</td><td align="left">Peptidase Inhibitor 15</td><td align="left">8q21.13</td><td align="left">1.73E-08</td><td align="left">5.18E-07</td><td align="left">Up</td></tr><tr><td align="left">AZGP1</td><td align="left">Alpha-2-glycoprotein 1, zinc-binding</td><td align="left">7q22.1</td><td align="left">1.96E-07</td><td align="left">4.41E-06</td><td align="left">Up</td></tr><tr><td align="left">PRRX1</td><td align="left">Paired Related Homeobox 1</td><td align="left">1q24.2</td><td align="left">2.73E-04</td><td align="left">3.51E-03</td><td align="left">Up</td></tr><tr><td align="left">AGR2</td><td align="left">Anterior Gradient 2</td><td align="left">7p21.1</td><td align="left">7.44E-04</td><td align="left">6.09E-03</td><td align="left">Up</td></tr><tr><td align="left">XIST</td><td align="left">X Inactive Specific Transcript</td><td align="left">Xq13.2</td><td align="left">1.04E-42</td><td align="left">4.66E-41</td><td align="left">Down</td></tr><tr><td align="left">PIGR</td><td align="left">Polymeric immunoglobulin receptor</td><td align="left">1q31-q41</td><td align="left">4.30E-07</td><td align="left">7.73E-06</td><td align="left">Down</td></tr><tr><td align="left">SFRP1</td><td align="left">Secreted Frizzled Related Protein 1</td><td align="left">8p11.21</td><td align="left">6.64E-07</td><td align="left">9.95E-06</td><td align="left">Down</td></tr><tr><td align="left">PLA2G2A</td><td align="left">Phospholipase A2 Group IIA</td><td align="left">1p36.13</td><td align="left">4.72E-04</td><td align="left">4.54E-03</td><td align="left">Down</td></tr><tr><td align="left">S100A2</td><td align="left">S100 Calcium Binding Protein A2</td><td align="left">1q21.3</td><td align="left">4.88E-04</td><td align="left">4.54E-03</td><td align="left">Down</td></tr><tr><td align="left">CHI3L1</td><td align="left">Chitinase 3 Like 1</td><td align="left">1q32.1</td><td align="left">5.05E-04</td><td align="left">4.54E-03</td><td align="left">Down</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec12"><title>Specific case</title><p id="Par40">Among all cases, only one lymph node metastasis specimen (Sample 16) was misclassified by the 90-gene expression assay, incorrectly identifying breast cancer as a neuroendocrine tumor. The top two results were neuroendocrine tumor with a similarity score of 54.6 and breast cancer with a similarity score of 35.5. The predicted result indicated it was a neuroendocrine tumor, which was inconsistent with the reference diagnosis.</p><p id="Par41">We further reviewed the clinicopathological information and performed additional IHC staining for neuroendocrine markers. This patient is a 69-year-old male who underwent seven months of tamoxifen neoadjuvant therapy followed by modified radical mastectomy. Microscopically, we observed eosinophilic change in tumor cell cytoplasm, tumor stroma fibrosis, and morphological features of locally metastatic lymph nodes showing neuroendocrine differentiation, along with post-treatment response. IHC markers including synaptophysin (Syn), chromogranin A (CgA), and INSM1 were all positive, consistent with the findings of the 90-gene expression assay. Finally, this case is diagnosed as male breast cancer with neuroendocrine differentiation. The histological morphology and IHC results of this case are depicted in Figure <xref rid="MOESM2" ref-type="media">S1</xref>.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par43">This study evaluated the potential diagnostic utility of the 90-gene expression assay for diagnosing MBC. The overall agreement of 96.7% (29/30) indicates the excellent performance of the 90-gene expression assay in identifying the tumor of origin in primary or metastatic MBC. The subgroup analysis shows consistency rates of 100% for PBT and DOM cases and 90.9% for LNM cases.</p><p id="Par44">In our previous study, we conducted two multicenter validation studies to evaluate the performance of the 90-gene expression assay in FBC. The results demonstrated accuracies of 97.8% (44/45) and 98.4% (121/123), respectively [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Additionally, Qifeng et al. also validated the 90-gene expression assay in primary and metastatic triple-negative breast cancer among females, showing an overall accuracy of 97.4% (112/115) [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, the results of all these studies in females are consistent with the present study&#x02019;s findings in males.</p><p id="Par45">Shaaban et al. compared the IHC patterns of MBC and FBC and reported that the proportion of ER-positive cases were significantly higher in MBC compared to FBC (80% vs. 68%), while PR-positive rates were similar (71% vs. 72%) [<xref ref-type="bibr" rid="CR23">23</xref>]. In our study, we observed higher ER and PR positivity rates, at 94.7% (18/19) and 85% (17/20), respectively, and a HER2 positivity of 15% (3/20). In addition to IHC-based findings, Callari et al. and Johansson et al. performed comprehensive analyses of gene expression patterns in MBC and FBC, identifying significant differences that underscore the notion that MBC and FBC are distinct diseases [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Our study aligns with these findings, revealing significant differential expression of 11 genes in MBC compared to FBC using the 90-gene expression assay. Specifically, five genes were up-regulated, and six genes were down-regulated in MBC. The <italic>RPS4Y1</italic> and <italic>XIST</italic> genes are located on sex chromosomes. Yuxi et al. investigated that <italic>XIST</italic>, a long noncoding RNA, has a role in promoting breast cancer stem cell self-renewal by derepressing let-7 controlled paracrine IL-6 proinflammatory signaling [<xref ref-type="bibr" rid="CR26">26</xref>]. <italic>AZGP1</italic> has been recognized as a crucial promoter in cancer metastasis and lipid metabolism [<xref ref-type="bibr" rid="CR27">27</xref>]. Higher expression of <italic>AZGP1</italic> in T cells has also been observed in MBC, as reported by Handong et al., suggesting the immunological and metabolic differences between MBC and FBC [<xref ref-type="bibr" rid="CR28">28</xref>]. Several studies have noted correlations between <italic>PI15</italic>,<italic> PRRX1</italic>,<italic> AGR2</italic>,<italic> PIGR</italic>,<italic> SFRP1</italic>,<italic> PLA2G2A</italic>,<italic> S100A2</italic>, and <italic>CHI3L1</italic> genes and breast cancer, but have not elucidated their differential expression in MBC and FBC [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. The diagnostic significance of these findings is particularly noteworthy. The differential expression of these genes may serve as potential biomarkers for understanding its unique metastatic behavior and guiding treatment approaches. Due to the rarity of MBC, researches on its molecular aspects are currently limited, but our findings provide valuable insights into its biological characteristics and clinical relevance. These results not only confirm the distinct molecular profiles of MBC and FBC but also underscore the need for further research to translate these findings into personalized diagnostic and therapeutic strategies.</p><p id="Par46">This study also had several limitations. First, cases of MBC with neuroendocrine differentiation might be misclassified as a neuroendocrine tumor rather than breast cancer. Second, the gene expression analysis was limited to 90 genes, which constrains the exploration of the broader molecular landscape. Future studies integrating transcriptomic sequencing and single-cell analysis could deeper insights into the molecular mechanisms underlying MBC [<xref ref-type="bibr" rid="CR37">37</xref>]. Additionally, exploring the role of ion channels, such as voltage-gated sodium channels (VGSCs) and transient receptor potential melastatin 7 (TRPM7), represents a promising avenue for identifying novel therapeutic targets in MBC [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par47">In conclusion, the 90-gene expression assay demonstrates high accuracy in diagnosing both primary and metastatic MBC, indicating its significant potential as a supplementary diagnostic tool for MBC. Incorporating this assay into pathological diagnoses holds the potential to empower oncologists with precision treatment options, ultimately enhancing the care and outcomes for patients with MBC. Furthermore, several molecular biomarkers may help elucidate the distinct mechanisms underlying MBC and FBC.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2024_13358_MOESM1_ESM.docx"><caption><p>Supplementary Material 1: Table S1. Antibodies characterization for immunostaining</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12885_2024_13358_MOESM2_ESM.tif"><caption><p>Supplementary Material 2: Fig. S1. The histologic features and immunohistochemical profiles of Sample 16. (A) Neuroendocrine differentiation of cells (200X). The tumor cells were (B) positive for CgA (200X). (C) Diffusely and strongly positive for Syn (200X). (D) Weakly positive for INSM1 (200X)</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AJCC</term><def><p id="Par5">American Joint Committee on Cancer</p></def></def-item><def-item><term>AR</term><def><p id="Par6">Androgen receptor</p></def></def-item><def-item><term>DOM</term><def><p id="Par7">Distant organ metastase</p></def></def-item><def-item><term>FBC</term><def><p id="Par8">Female breast cancer</p></def></def-item><def-item><term>FFPE</term><def><p id="Par9">Formalin-fixed, paraffin-embedded</p></def></def-item><def-item><term>FNA</term><def><p id="Par10">Fine-needle aspiration</p></def></def-item><def-item><term>FUSCC</term><def><p id="Par11">Fudan University Shanghai Cancer Center</p></def></def-item><def-item><term>GCDFP15</term><def><p id="Par12">Gross cystic disease fluid protein-15</p></def></def-item><def-item><term>LNM</term><def><p id="Par13">Lymph node metastase</p></def></def-item><def-item><term>MBC</term><def><p id="Par14">Male breast cancer</p></def></def-item><def-item><term>MGB</term><def><p id="Par15">Mammaglobin</p></def></def-item><def-item><term>NCB</term><def><p id="Par16">Needle core biopsy</p></def></def-item><def-item><term>PBT</term><def><p id="Par17">Primary breast tumor</p></def></def-item><def-item><term>TRPM7</term><def><p id="Par18">Transient receptor potential melastatin 7</p></def></def-item><def-item><term>VGSC</term><def><p id="Par19">Voltage-gated sodium channels</p></def></def-item><def-item><term>WHO</term><def><p id="Par20">World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jing Liu and Yifeng Sun have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>QF W and SL H designed the study. J L and QF W provided the specimens and collected clinical information. J L, YF S, P Q, YX W, Y P and QH X performed the experiments and analyzed all data. J L and YF S wrote the initial manuscript draft. QH X, MD X, SL H, and QF W critically revised the manuscript and gave valuable insight into the study concept. All authors revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by research funding from the National Natural Science Foundation of China grants 81,972,728 (QF W) and 82,272,626 (QF W) and Canhelp Genomics Co., Ltd.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par49">The study was performed in accordance with the ethical standards of the Declaration of Helsinki. Ethics approval for the study was granted by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center (FUSCC, Shanghai, China). Additionally, informed consent to participate was obtained from each and every participant.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par50">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">Author YF S, YX W and QH X were employed by the company Canhelp Genomics Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>7. References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>S</given-names></name><name><surname>Speirs</surname><given-names>V</given-names></name><name><surname>Shaaban</surname><given-names>AM</given-names></name></person-group><article-title>Male breast cancer: an update</article-title><source>Virchows Arch</source><year>2022</year><volume>480</volume><issue>1</issue><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s00428-021-03190-7</pub-id><pub-id pub-id-type="pmid">34458944</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Arch. 2022;480(1):85&#x02013;93. 10.1007/s00428-021-03190-7.<pub-id pub-id-type="pmid">34458944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Wagle</surname><given-names>NS</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2023</article-title><source>CA Cancer J Clin</source><year>2023</year><volume>73</volume><issue>1</issue><fpage>17</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3322/caac.21763</pub-id><pub-id pub-id-type="pmid">36633525</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17&#x02013;48. 10.3322/caac.21763.<pub-id pub-id-type="pmid">36633525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelwahab Yousef</surname><given-names>AJ</given-names></name></person-group><article-title>Male breast Cancer: epidemiology and risk factors</article-title><source>Semin Oncol</source><year>2017</year><volume>44</volume><issue>4</issue><fpage>267</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2017.11.002</pub-id><pub-id pub-id-type="pmid">29526255</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Abdelwahab Yousef AJ. Male breast Cancer: epidemiology and risk factors. Semin Oncol. 2017;44(4):267&#x02013;72. 10.1053/j.seminoncol.2017.11.002.<pub-id pub-id-type="pmid">29526255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Losurdo</surname><given-names>A</given-names></name><name><surname>Rota</surname><given-names>S</given-names></name><name><surname>Gullo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature</article-title><source>Crit Rev Oncol Hematol</source><year>2017</year><volume>113</volume><fpage>283</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2017.03.013</pub-id><pub-id pub-id-type="pmid">28427518</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Losurdo A, Rota S, Gullo G, et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit Rev Oncol Hematol. 2017;113:283&#x02013;91. 10.1016/j.critrevonc.2017.03.013.<pub-id pub-id-type="pmid">28427518</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanguinetti</surname><given-names>A</given-names></name><name><surname>Polistena</surname><given-names>A</given-names></name><name><surname>Lucchini</surname><given-names>R</given-names></name><etal/></person-group><article-title>Male breast cancer, clinical presentation, diagnosis and treatment: twenty years of experience in our breast unit</article-title><source>Int J Surg Case Rep</source><year>2016</year><volume>20S</volume><issue>Suppl</issue><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.ijscr.2016.02.004</pub-id><pub-id pub-id-type="pmid">26994487</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sanguinetti A, Polistena A, Lucchini R, et al. Male breast cancer, clinical presentation, diagnosis and treatment: twenty years of experience in our breast unit. Int J Surg Case Rep. 2016;20S(Suppl):8&#x02013;11. 10.1016/j.ijscr.2016.02.004.<pub-id pub-id-type="pmid">26994487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Heller</surname><given-names>SL</given-names></name><name><surname>Moy</surname><given-names>L</given-names></name></person-group><article-title>Male breast Cancer in the age of genetic testing: an opportunity for early detection, tailored therapy, and Surveillance</article-title><source>Radiographics</source><year>2018</year><volume>38</volume><issue>5</issue><fpage>1289</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1148/rg.2018180013</pub-id><pub-id pub-id-type="pmid">30074858</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gao Y, Heller SL, Moy L. Male breast Cancer in the age of genetic testing: an opportunity for early detection, tailored therapy, and Surveillance. Radiographics. 2018;38(5):1289&#x02013;311. 10.1148/rg.2018180013.<pub-id pub-id-type="pmid">30074858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>K</given-names></name><name><surname>Martaindale</surname><given-names>S</given-names></name><name><surname>Whitman</surname><given-names>GJ</given-names></name></person-group><article-title>Male breast magnetic resonance imaging: when is it helpful? Our experience over the last decade</article-title><source>Curr Probl Diagn Radiol</source><year>2019</year><volume>48</volume><issue>3</issue><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1067/j.cpradiol.2018.01.002</pub-id><pub-id pub-id-type="pmid">29454681</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Shin K, Martaindale S, Whitman GJ. Male breast magnetic resonance imaging: when is it helpful? Our experience over the last decade. Curr Probl Diagn Radiol. 2019;48(3):196&#x02013;203. 10.1067/j.cpradiol.2018.01.002.<pub-id pub-id-type="pmid">29454681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Draghi</surname><given-names>F</given-names></name><name><surname>Tarantino</surname><given-names>CC</given-names></name><name><surname>Madonia</surname><given-names>L</given-names></name><name><surname>Ferrozzi</surname><given-names>G</given-names></name></person-group><article-title>Ultrasonography of the male breast</article-title><source>J Ultrasound</source><year>2011</year><volume>14</volume><issue>3</issue><fpage>122</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jus.2011.06.004</pub-id><pub-id pub-id-type="pmid">23397020</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Draghi F, Tarantino CC, Madonia L, Ferrozzi G. Ultrasonography of the male breast. J Ultrasound. 2011;14(3):122&#x02013;9. 10.1016/j.jus.2011.06.004.<pub-id pub-id-type="pmid">23397020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Bootsma</surname><given-names>TI</given-names></name><name><surname>Duijveman</surname><given-names>P</given-names></name><name><surname>Pijpe</surname><given-names>A</given-names></name><name><surname>Scheelings</surname><given-names>PC</given-names></name><name><surname>Witkamp</surname><given-names>AJ</given-names></name><name><surname>Bleiker</surname><given-names>EMA</given-names></name></person-group><article-title>Unmet information needs of men with breast cancer and health professionals</article-title><source>Psychooncology</source><year>2020</year><volume>29</volume><issue>5</issue><fpage>851</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/pon.5356</pub-id><pub-id pub-id-type="pmid">32040237</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bootsma TI, Duijveman P, Pijpe A, Scheelings PC, Witkamp AJ, Bleiker EMA. Unmet information needs of men with breast cancer and health professionals. Psychooncology. 2020;29(5):851&#x02013;60. 10.1002/pon.5356.<pub-id pub-id-type="pmid">32040237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>I</given-names></name><name><surname>Hassan</surname><given-names>H</given-names></name><name><surname>Sofianopoulou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><issue>9</issue><fpage>1660</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01940-1</pub-id><pub-id pub-id-type="pmid">36115878</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Allen I, Hassan H, Sofianopoulou E, et al. Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis. Br J Cancer. 2022;127(9):1660&#x02013;9. 10.1038/s41416-022-01940-1.<pub-id pub-id-type="pmid">36115878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Asao</surname><given-names>T</given-names></name><name><surname>Tobias</surname><given-names>GC</given-names></name><name><surname>Lucotti</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Matei</surname><given-names>I</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group><article-title>Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications</article-title><source>Extracell Vesicles Circ Nucleic Acids</source><year>2023</year><volume>4</volume><issue>3</issue><fpage>461</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.20517/evcna.2023.37</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Asao T, Tobias GC, Lucotti S, Jones DR, Matei I, Lyden D. Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications. Extracell Vesicles Circ Nucleic Acids. 2023;4(3):461&#x02013;85. 10.20517/evcna.2023.37.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Teicher</surname><given-names>BA</given-names></name></person-group><article-title>Cancer treatments: past, present, and future</article-title><source>Cancer Genet</source><year>2024</year><volume>286&#x02013;287</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2024.06.002</pub-id><pub-id pub-id-type="pmid">38909530</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286&#x02013;287:18&#x02013;24. 10.1016/j.cancergen.2024.06.002.<pub-id pub-id-type="pmid">38909530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Eibl</surname><given-names>RH</given-names></name><name><surname>Schneemann</surname><given-names>M</given-names></name></person-group><article-title>Cell-free DNA as a biomarker in cancer</article-title><source>Extracell Vesicles Circ Nucleic Acids</source><year>2022</year><volume>3</volume><issue>3</issue><fpage>178</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.20517/evcna.2022.20</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Eibl RH, Schneemann M. Cell-free DNA as a biomarker in cancer. Extracell Vesicles Circ Nucleic Acids. 2022;3(3):178&#x02013;98. 10.20517/evcna.2022.20.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development and clinical validation of a 90-Gene expression assay for identifying Tumor tissue origin</article-title><source>J Mol Diagn</source><year>2020</year><volume>22</volume><issue>9</issue><fpage>1139</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2020.06.005</pub-id><pub-id pub-id-type="pmid">32610162</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ye Q, Wang Q, Qi P, et al. Development and clinical validation of a 90-Gene expression assay for identifying Tumor tissue origin. J Mol Diagn. 2020;22(9):1139&#x02013;50. 10.1016/j.jmoldx.2020.06.005.<pub-id pub-id-type="pmid">32610162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s12967-022-03318-6</pub-id><pub-id pub-id-type="pmid">35255924</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Sun W, Wu W, Wang Q, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Transl Med. 2022;20(1):114. 10.1186/s12967-022-03318-6.<pub-id pub-id-type="pmid">35255924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial</article-title><source>Lancet Oncol</source><year>2024</year><volume>25</volume><issue>8</issue><fpage>1092</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(24)00313-9</pub-id><pub-id pub-id-type="pmid">39068945</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu X, Zhang X, Jiang S, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024;25(8):1092&#x02013;102. 10.1016/S1470-2045(24)00313-9.<pub-id pub-id-type="pmid">39068945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>AE</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><article-title>Eighth Edition of the AJCC Cancer staging Manual: breast Cancer</article-title><source>Ann Surg Oncol</source><year>2018</year><volume>25</volume><issue>7</issue><fpage>1783</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1245/s10434-018-6486-6</pub-id><pub-id pub-id-type="pmid">29671136</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer staging Manual: breast Cancer. Ann Surg Oncol. 2018;25(7):1783&#x02013;5. 10.1245/s10434-018-6486-6.<pub-id pub-id-type="pmid">29671136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lebeau</surname><given-names>A</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name></person-group><article-title>[Updated WHO classification of tumors of the breast: the most important changes]</article-title><source>Pathologe</source><year>2021</year><volume>42</volume><issue>3</issue><fpage>270</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s00292-021-00934-9</pub-id><pub-id pub-id-type="pmid">33822251</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lebeau A, Denkert C. [Updated WHO classification of tumors of the breast: the most important changes]. Pathologe. 2021;42(3):270&#x02013;80. 10.1007/s00292-021-00934-9.<pub-id pub-id-type="pmid">33822251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up</article-title><source>Histopathology</source><year>1991</year><volume>19</volume><issue>5</issue><fpage>403</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.1991.tb00229.x</pub-id><pub-id pub-id-type="pmid">1757079</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403&#x02013;10. 10.1111/j.1365-2559.1991.tb00229.x.<pub-id pub-id-type="pmid">1757079</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Qi P, Sun Y, Pang Y, et al. Diagnostic utility of a 90-Gene expression assay (Canhelp-Origin) for patients with metastatic Cancer with an unclear or unknown diagnosis. Mol Diagn Ther Published Online September. 2024;27. 10.1007/s40291-024-00746-6.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Gene expression profiling for Differential diagnosis of Liver metastases: a Multicenter, Retrospective Cohort Study</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>725988</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.725988</pub-id><pub-id pub-id-type="pmid">34631555</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wang Q, Li F, Jiang Q, et al. Gene expression profiling for Differential diagnosis of Liver metastases: a Multicenter, Retrospective Cohort Study. Front Oncol. 2021;11:725988. 10.3389/fonc.2021.725988.<pub-id pub-id-type="pmid">34631555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gene expression profiling for diagnosis of Triple-negative breast Cancer: a Multicenter, Retrospective Cohort Study</article-title><source>Front Oncol</source><year>2019</year><volume>9</volume><fpage>354</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00354</pub-id><pub-id pub-id-type="pmid">31134153</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang Q, Xu M, Sun Y, et al. Gene expression profiling for diagnosis of Triple-negative breast Cancer: a Multicenter, Retrospective Cohort Study. Front Oncol. 2019;9:354. 10.3389/fonc.2019.00354.<pub-id pub-id-type="pmid">31134153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Shaaban</surname><given-names>AM</given-names></name><name><surname>Ball</surname><given-names>GR</given-names></name><name><surname>Brannan</surname><given-names>RA</given-names></name><etal/></person-group><article-title>A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences</article-title><source>Breast Cancer Res Treat</source><year>2012</year><volume>133</volume><issue>3</issue><fpage>949</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s10549-011-1856-9</pub-id><pub-id pub-id-type="pmid">22094935</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Shaaban AM, Ball GR, Brannan RA, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012;133(3):949&#x02013;58. 10.1007/s10549-011-1856-9.<pub-id pub-id-type="pmid">22094935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker</article-title><source>Breast Cancer Res</source><year>2012</year><volume>14</volume><issue>1</issue><fpage>R31</fpage><pub-id pub-id-type="doi">10.1186/bcr3116</pub-id><pub-id pub-id-type="pmid">22333393</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Johansson I, Nilsson C, Berglund P, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res. 2012;14(1):R31. 10.1186/bcr3116.<pub-id pub-id-type="pmid">22333393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Callari</surname><given-names>M</given-names></name><name><surname>Cappelletti</surname><given-names>V</given-names></name><name><surname>De Cecco</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>127</volume><issue>3</issue><fpage>601</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-1015-8</pub-id><pub-id pub-id-type="pmid">20625818</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Callari M, Cappelletti V, De Cecco L, et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011;127(3):601&#x02013;10. 10.1007/s10549-010-1015-8.<pub-id pub-id-type="pmid">20625818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><etal/></person-group><article-title>LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling</article-title><source>Oncogene</source><year>2023</year><volume>42</volume><issue>18</issue><fpage>1419</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02652-3</pub-id><pub-id pub-id-type="pmid">36922677</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ma Y, Zhu Y, Shang L, et al. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling. Oncogene. 2023;42(18):1419&#x02013;37. 10.1038/s41388-023-02652-3.<pub-id pub-id-type="pmid">36922677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Ke</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>AZGP1 is androgen responsive and involved in AR-induced prostate cancer cell proliferation and metastasis</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><issue>10</issue><fpage>17444</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/jcp.28366</pub-id><pub-id pub-id-type="pmid">30820960</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Cao R, Ke M, Wu Q, et al. AZGP1 is androgen responsive and involved in AR-induced prostate cancer cell proliferation and metastasis. J Cell Physiol. 2019;234(10):17444&#x02013;58. 10.1002/jcp.28366.<pub-id pub-id-type="pmid">30820960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>5590</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41318-2</pub-id><pub-id pub-id-type="pmid">37696831</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Sun H, Zhang L, Wang Z, et al. Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer. Nat Commun. 2023;14(1):5590. 10.1038/s41467-023-41318-2.<pub-id pub-id-type="pmid">37696831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Mu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Stachydrine represses the proliferation and enhances cell cycle arrest and apoptosis of breast cancer cells via PLA2G2A/DCN axis</article-title><source>Chem Biol Drug Des</source><year>2024</year><volume>103</volume><issue>1</issue><fpage>e14429</fpage><pub-id pub-id-type="doi">10.1111/cbdd.14429</pub-id><pub-id pub-id-type="pmid">38230769</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhai Z, Mu T, Zhao L, et al. Stachydrine represses the proliferation and enhances cell cycle arrest and apoptosis of breast cancer cells via PLA2G2A/DCN axis. Chem Biol Drug Des. 2024;103(1):e14429. 10.1111/cbdd.14429.<pub-id pub-id-type="pmid">38230769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Rusak</surname><given-names>A</given-names></name><name><surname>Jablonska</surname><given-names>K</given-names></name><name><surname>Piotrowska</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of CHI3L1 expression in angiogenesis in invasive ductal breast carcinoma</article-title><source>Anticancer Res</source><year>2018</year><volume>38</volume><issue>6</issue><fpage>3357</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.21873/anticanres.12602</pub-id><pub-id pub-id-type="pmid">29848684</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Rusak A, Jablonska K, Piotrowska A, et al. The role of CHI3L1 expression in angiogenesis in invasive ductal breast carcinoma. Anticancer Res. 2018;38(6):3357&#x02013;66. 10.21873/anticanres.12602.<pub-id pub-id-type="pmid">29848684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name></person-group><article-title>Mir-325-3p promotes the Proliferation, Invasion, and EMT of breast Cancer cells by directly targeting S100A2</article-title><source>Oncol Res</source><year>2021</year><volume>28</volume><issue>7</issue><fpage>731</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.3727/096504020X16100888208039</pub-id><pub-id pub-id-type="pmid">33419488</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang H, Hu X, Yang F, Xiao H. Mir-325-3p promotes the Proliferation, Invasion, and EMT of breast Cancer cells by directly targeting S100A2. Oncol Res. 2021;28(7):731&#x02013;44. 10.3727/096504020X16100888208039.<pub-id pub-id-type="pmid">33419488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>ZH</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Yue</surname><given-names>JX</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name></person-group><article-title>Comprehensive Analysis of the expression and prognosis for SFRPs in breast carcinoma</article-title><source>Cell Transpl</source><year>2020</year><volume>29</volume><fpage>963689720962479</fpage><pub-id pub-id-type="doi">10.1177/0963689720962479</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wu ZH, Zhang YJ, Yue JX, Zhou T. Comprehensive Analysis of the expression and prognosis for SFRPs in breast carcinoma. Cell Transpl. 2020;29:963689720962479. 10.1177/0963689720962479.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Asanprakit</surname><given-names>W</given-names></name><name><surname>Lobo</surname><given-names>DN</given-names></name><name><surname>Eremin</surname><given-names>O</given-names></name><name><surname>Bennett</surname><given-names>AJ</given-names></name></person-group><article-title>Expression of polymeric immunoglobulin receptor (PIGR) and the effect of PIGR overexpression on breast cancer cells</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>16606</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-43946-6</pub-id><pub-id pub-id-type="pmid">37789066</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Asanprakit W, Lobo DN, Eremin O, Bennett AJ. Expression of polymeric immunoglobulin receptor (PIGR) and the effect of PIGR overexpression on breast cancer cells. Sci Rep. 2023;13(1):16606. 10.1038/s41598-023-43946-6.<pub-id pub-id-type="pmid">37789066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>de Moraes</surname><given-names>CL</given-names></name><name><surname>Cruz</surname><given-names>E</given-names></name><name><surname>Melo</surname><given-names>N</given-names></name><name><surname>Valoyes</surname><given-names>MAV</given-names></name></person-group><article-title>Naves do Amaral W. AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer</article-title><source>Clin Breast Cancer</source><year>2022</year><volume>22</volume><issue>2</issue><fpage>e242</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2021.07.008</pub-id><pub-id pub-id-type="pmid">34462207</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">de Moraes CL, Cruz E, Melo N, Valoyes MAV. Naves do Amaral W. AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer. Clin Breast Cancer. 2022;22(2):e242&#x02013;52. 10.1016/j.clbc.2021.07.008.<pub-id pub-id-type="pmid">34462207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>CJ</given-names></name><name><surname>Mitchell</surname><given-names>AV</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA</article-title><source>Oncogene</source><year>2021</year><volume>40</volume><issue>46</issue><fpage>6430</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-02030-x</pub-id><pub-id pub-id-type="pmid">34608266</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Block CJ, Mitchell AV, Wu L, et al. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA. Oncogene. 2021;40(46):6430&#x02013;42. 10.1038/s41388-021-02030-x.<pub-id pub-id-type="pmid">34608266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Rathi</surname><given-names>A</given-names></name><name><surname>Minocha</surname><given-names>R</given-names></name><etal/></person-group><article-title>Breast Cancer prognostic hub genes identified by Integrated Transcriptomic and Weighted Network Analysis: a Road toward Personalized Medicine</article-title><source>OMICS</source><year>2023</year><volume>27</volume><issue>5</issue><fpage>227</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1089/omi.2023.0033</pub-id><pub-id pub-id-type="pmid">37155625</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Singh P, Rathi A, Minocha R, et al. Breast Cancer prognostic hub genes identified by Integrated Transcriptomic and Weighted Network Analysis: a Road toward Personalized Medicine. OMICS. 2023;27(5):227&#x02013;36. 10.1089/omi.2023.0033.<pub-id pub-id-type="pmid">37155625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Rasteh</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name></person-group><article-title>Identification of the novel exhausted T cell CD8&#x02009;+&#x02009;markers in breast cancer</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>19142</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-70184-1</pub-id><pub-id pub-id-type="pmid">39160211</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Liu H, Dong A, Rasteh AM, Wang P, Weng J. Identification of the novel exhausted T cell CD8&#x02009;+&#x02009;markers in breast cancer. Sci Rep. 2024;14(1):19142. 10.1038/s41598-024-70184-1.<pub-id pub-id-type="pmid">39160211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>CLH</given-names></name><name><surname>Jackson</surname><given-names>AP</given-names></name></person-group><article-title>Voltage-gated sodium channels in cancers</article-title><source>Biomark Res</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s40364-024-00620-x</pub-id><pub-id pub-id-type="pmid">39060933</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Liu H, Weng J, Huang CLH, Jackson AP. Voltage-gated sodium channels in cancers. Biomark Res. 2024;12(1):70. 10.1186/s40364-024-00620-x.<pub-id pub-id-type="pmid">39060933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Dilger</surname><given-names>JP</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>The role of transient receptor potential melastatin 7 (TRPM7) in cell viability: a potential target to suppress breast Cancer cell cycle</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>131</fpage><pub-id pub-id-type="doi">10.3390/cancers12010131</pub-id><pub-id pub-id-type="pmid">31947967</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Liu H, Dilger JP, Lin J. The role of transient receptor potential melastatin 7 (TRPM7) in cell viability: a potential target to suppress breast Cancer cell cycle. Cancers (Basel). 2020;12(1):131. 10.3390/cancers12010131.<pub-id pub-id-type="pmid">31947967</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>